Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: A national study

American Journal of Gastroenterology

Volumn 106, Issue 3, 2011, Pages 483-491

  Kramer, Jennifer R ^a,b   Kanwal, Fasiha ^c   Richardson, Peter ^a,b   Giordano, Thomas P ^a,b   Petersen, Laura A ^a,b   El Serag, Hashem B ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; HEMOGLOBIN;

ADULT; AFRICAN AMERICAN; AGE; AGED; ALCOHOL ABUSE; ANXIETY; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG ABUSE; FEMALE; GENOTYPE; HEALTH CARE DISPARITY; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; POSTTRAUMATIC STRESS DISORDER; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; UNITED STATES; VETERAN; VIREMIA;

ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; COMORBIDITY; DRUG PRESCRIPTIONS; FEMALE; HEALTH FACILITIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PREDICTIVE VALUE OF TESTS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SEX FACTORS; UNITED STATES; VETERANS; VIREMIA;

EID: 79952362218     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.430     Document Type: Article

References (51)

1. Armstrong GL, Wasley A, Simard EP et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14. (Pubitemid 46780630)
2. Di Bisceglie AM, Goodman ZD, Ishak KG et al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.
3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32. (Pubitemid 27129209)
4. Tsukuma H, Hiyama T, Tanaka S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease (see comments). N Engl J Med 1993;328:1797-801. (Pubitemid 23174709)
5. Ikeda K, Saitoh S, Koida I et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53. (Pubitemid 23193616)
6. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50. (Pubitemid 29114292)
7. El Serag HB, Davila JA, Petersen NJ et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-23.
8. Austin GE, Jensen B, Leete J et al. Prevalence of hepatitis C virus seropositivity among hospitalized US veterans. Am J Med Sci 2000; 319:353-9. (Pubitemid 30416062)
9. Briggs M, Baker C, Hall R et al. Prevalence and risk factors for hepatitis C virus infection at an urban veterans administration medical center. Hepatology 2001;34:1200-5. (Pubitemid 33096593)
10. Cheung RC. Epidemiology of hepatitis C virus infection in American veterans (see comments). Am J Gastroenterol 2000;95:740-7. (Pubitemid 30123913)
11. Dominitz JA, Boyko EJ, Koepsell TD et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 2005;41:88-96. (Pubitemid 40066386)
12. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160:3227-30.
13. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9. (Pubitemid 28543497)
14. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
15. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
16. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32. (Pubitemid 28510876)
17. Bini EJ, Mehandru S. Sustained virological response rates and healthrelated quality of life aft er interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Aliment Pharmacol Ther 2006;23:777-85. (Pubitemid 43344597)
18. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13. (Pubitemid 34465173)
19. Shiratori Y, Ito Y, Yokosuka O et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105-14.
20. Spiegel BM, Younossi ZM, Hays RD et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005;41:790-800. (Pubitemid 40462941)
21. Department of Veterans Affairs Hepatitis Yee HS ## Currie SL, Darling JM et al. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am J Gastroenterol 2006 101 2360-78. (Pubitemid 44477566)
22. Butt AA, Wagener M, Shakil AO et al. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 2005;12:81-5. (Pubitemid 40188778)
23. Butt AA, Justice AC, Skanderson M et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007;56:385-9. (Pubitemid 46579770)
24. Kanwal F, Hoang T, Spiegel BM et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007;46:1741-9.
25. Bini EJ, Brau N, Currie S et al. Prospective multicenter study of eligibility for antiviral therapy among 4084 US veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005;100:1772-9. (Pubitemid 41648433)
26. Cawthorne CH, Rudat KR, Burton MS et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 2002;97:149-55. (Pubitemid 34059779)
27. Witkos M, Yi QL, Heathcote J et al. Predictors of antiviral therapy in a posttransfusion cohort of hepatitis C patients. Can J Gastroenterol 2006;20:107-11.
28. Falck-Ytter Y, Kale H, Mullen KD et al. Surprisingly small Effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-92. (Pubitemid 34150758)
29. Kim C, Hofer TP, Kerr EA. Review of evidence and explanations for suboptimal screening and treatment of dyslipidemia in women. A conceptual model. J Gen Intern Med 2003;18:854-63. (Pubitemid 37281781)
30. Herman WH. More than provider specialty. Med Care 2000;38:128-30.
31. Landon BE, Wilson IB, Cleary PD. A conceptual model of the Effects of health care organizations on the quality of medical care. JAMA 1998;279:1377-82. (Pubitemid 28198805)
32. McNeil BJ, Pedersen SH, Gatsonis C. Current issues in profiling quality of care. Inquiry 1992;29:298-307.
33. Westert GP, Groenewegen PP. Medical practice variations: changing the theoretical approach. Scand J Public Health 1999;27:173-80. (Pubitemid 30619668)
34. Ashton CM, Petersen NJ, Souchek J et al. Geographic variations in utilization rates in Veterans Affairs hospitals and clinics. N Engl J Med 1999;340:32-9. (Pubitemid 29024682)
35. McGinn J, Davis C. Geographic variation, physician characteristics, and diabetes care disparities in a metropolitan area, 2003-2004. Diabetes Res Clin Pract 2006;72:162-9.
36. Schultz EM, Powell AA, McMillan A et al. Hospital characteristics associated with timeliness of care in veterans with lung cancer. Am J Respir Crit Care Med 2009;179:595-600.
37. Backus LI, Gavrilov S, Loomis TP et al. Clinical Case Registries: simultaneous local and national disease registries for population quality management . J Am Med Inform Assoc 2009;16:775-83.
38. VA Information Resource Center. http://vaww.virec.research.va.gov/Data- SourcesName/DataNames.htm # VitalStatus 30 September 2008.
39. Petersen LA, Pietz K, Woodard LD et al. Comparison of the predictive validity of diagnosis-based risk adjusters for clinical outcomes. Med Care 2005;43:61-7. (Pubitemid 40137615)
40. Byrne MM, Daw CN, Nelson HA et al. Method to develop health care peer groups for quality and financial comparisons across hospitals. Health Serv Res 2009;44:577-92.
41. Brookhart MA, Solomon DH, Wang P et al. Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. J Clin Epidemiol 2006;59:18-25. (Pubitemid 41797471)
42. Efron B. Regression and Anova with zero-one data - measures of residual variation. J Am Stat Assoc 1978;73:113-21.
43. Backus LI, Boothroyd DB, Phillips BR et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007;46:37-47. (Pubitemid 47171919)
44. Beste LA, Straits-Troster K, Zickmund S et al. Specialty care and education associated with greater disease-specific knowledge but not satisfaction with care for chronic hepatitis C. Aliment Pharmacol Ther 2009;30:275-82.
45. Pietz K, O ' Malley KJ, Byrne M et al. Physician-level variation in practice patterns in the VA healthcare system. Health Serv Outcome Res Methodol 2002;3:95-106. (Pubitemid 36889731)
46. Krein SL, Hofer TP, Kerr EA et al. Whom should we profile? Examining diabetes care practice variation among primary care providers, provider groups, and health care facilities. Health Serv Res 2002;37:1159-80. (Pubitemid 35398454)
47. Tuerk PW, Mueller M, Egede LE. Estimating physician Effects on glycemic control in the treatment of diabetes: methods, Effects sizes, and implications for treatment policy. Diabetes Care 2008;31:869-73.
48. Katon W, Rutter CM, Lin E et al. Are there detectable differences in quality of care or outcome of depression across primary care providers? Med Care 2000;38:552-61.
49. Kramer JR, Davila JA, Miller ED et al. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther 2008;27:274-82.
50. Wilson NJ, Kizer KW. The VA health care system: an unrecognized national safety net. Health Aff (Millwood) 1997;16:200-4. (Pubitemid 127464343)
51. Yu W, Ravelo A, Wagner TH et al. Prevalence and costs of chronic conditions in the VA health care system. Med Care Res Rev 2003;60:146S-67S. (Pubitemid 36993500)